Shionogi finalizes agreement to acquire Japan Tobacco's pharmaceutical business

Shionogi & Co., Ltd. has officially executed an absorption-type company split agreement with Japan Tobacco Inc. to succeed its pharmaceutical business. This follows a previous announcement on May 7, 2025, regarding the initial agreement and the acquisition of shares in Akros Pharma Inc. to make it a sub-subsidiary of Shionogi. The transaction, categorized as a simplified absorption-type split, will proceed without shareholder approval from either company.

The finalized schedule for the absorption-type split includes the board resolution for the split agreement on September 12, 2025, and the execution of the absorption-type split agreement on September 25, 2025. The effective date of the absorption-type split is set for December 25, 2025. This schedule may be adjusted based on regulatory approvals and other factors.